Science Pool

Bioinformatics supporting Infectious Disease: Creating knowledge for efficient discovery and development of better medicines.​

Pathogen functional genomics analyses for unbiased, multidimensional small molecule effect characterisation (RNA-, DNA-seq analyses to characterise pathogen genome and transcriptome)

Genome assembly and annotation with a focus on resistance and virulence (Illumina, ONT, hybrid)

• Short- (SNP, short indels) and long-range (insertion, deletion, inversion, translocation, duplication) variant analysis associated with resistance (Illumina, ONT)
• Bacterial genome wide association study (GWAS)
• Transcriptome analysis (RNAseq) and functional interpretation
• Bacterial population sequencing and variant characterisation (PoolSeq)
• Molecular phylogeny
• Network analysis (enrichment analysis, pathway mapping)

DOWNLOAD

Despite recent reinvigorated efforts in Tuberculosis (TB) drug discovery, relatively few new drugs and candidates have emerged with clear utility against drug resistant TB. However, significant technological advances and learnings around target value have taken place offering opportunities to re-assess the potential for optimization of previously discovered chemical matter against Mycobacterium tuberculosis. A re-assessment of discarded compounds and programs from the “golden age of antibiotics” has yielded new scaffolds and targets against TB and uncovered classes with previously unappreciated utility for TB.

In this recent review, written by Evotec TB experts, Christine Roubert, Evelyne Fontaine and Anna Upton, these new perspectives, and the progress of these approaches are summarized, together with evident advantages and limitations of these strategies.

READ NOW

Date: 3 - 6 November, 2022

Attendee: Tobias Bohnenpoll (Research Scientist, Metabolic Diseases)

Our scientific program:

Poster: Unsupervised Characterization of the NURTuRE Cohort Reveals Gene Expression and Tissue Remodeling Dynamics Along a Synthetic CKD Progression Axis

Presented by Tobias Bohnenpoll, Ph.D., Research Scientist at Evotec on 5 November from 10:00am - 12:00pm EDT

Oral Abstract Session: A Multi-Omics Approach to IgA Nephropathy Characterization in the NURTuRE Cohort Enables Precision-Based Treatment Approaches

This live presentation will showcase work done within a strategic partnership between Evotec SE and Chinook Therapeutics. 

Presented by Eric Olson, Ph.D., Director, Bioinformatics and Computational Biology at Chinook Therapeutics on 4 November from 4:30 - 6:00pm EDT

Our popular, easy-to-follow guide: 'Everything you need to know about ADME' is now on its 5th edition.

Read about:

• an in-depth overview of physicochemical properties, drug metabolism, permeability and drug transporters, drug-drug interactions and plasma protein binding
• an assessment for current methods available for determining ADME properties 
• how ADME data are interpreted and used
• relevance to the regulatory guidance

LEARN MORE